Compare BAK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | COLL |
|---|---|---|
| Founded | 1972 | 2002 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2002 | 2015 |
| Metric | BAK | COLL |
|---|---|---|
| Price | $3.75 | $33.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.40 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 3.3M | 557.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $16.02 | $8.01 |
| Revenue Next Year | $7.04 | N/A |
| P/E Ratio | ★ N/A | $20.19 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $2.32 | $25.87 |
| 52 Week High | $5.30 | $50.79 |
| Indicator | BAK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 38.00 |
| Support Level | $3.36 | $31.18 |
| Resistance Level | $3.97 | $36.20 |
| Average True Range (ATR) | 0.28 | 1.26 |
| MACD | 0.01 | 0.49 |
| Stochastic Oscillator | 39.52 | 33.83 |
Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.